The Effects of Phototherapy in Preterm Infants Pda

Chest Shielding for Prevention of a Patent Ductus Arteriosus in Preterm Infants Receiving Phototherapy Effect of Phototherapy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03675425

Enrollment

Registered

2018-09-18

Start date

2018-07-08

Completion date

2019-02-28

Last updated

2018-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyper Bilirubinemia, Patent Ductus Arteriosus After Premature Birth

Keywords

Chest shielding, Patent Ductus Arteriosus, Chest Childing

Brief summary

The study was designed to assess whether chest shielding during phototherapy reduces the incidence of PDA, as assessed by serial echocardiographic examinations, in a population of extremely preterm infants born at lower 30 week gestation.

Detailed description

Phototherapy is a therapeutic intervention frequently used for management of neonatal hyperbilirubinaemia in extremely premature infants, especially in the first week when patency of the ductus is a clinical problem. Phototherapy has also been implicated in increased ductal patency. One randomized, controlled trial showed that chest shielding during phototherapy reduced the incidence and severity of PDA by 50% in preterm infants. These findings were mainly based on clinical evaluation of the ductus with echocardiographic studies performed only on a subgroup of infants noted to have a murmur on clinical examination.

Interventions

OTHERGroup 1: non chest shielding

non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,

OTHERGroup 2: chest shielding

chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

3 Days to 1 Weeks

Healthy volunteers

Inclusion criteria

* Gestational week ≤ 30 weeks receiving phototherapy due to jaundice and infants who can perform echocardiography before and after treatment will be included in the study.

Exclusion criteria

* Babies with congenital heart disease. * Infants with major structural anomalies and infants who can not undergo echocardiography before or after treatment.

Design outcomes

Primary

Measure	Time frame	Description
echocardiographic examination	first week	presence of Patent Ductus arteriozus

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026